Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
Berenson A et al. Ann Hematol. 2016 Dec 8. [Epub ahead of print].

Practical Considerations in Managing Relapsed Multiple Myeloma.
Agarwal A et al. Clin Lymphoma Myeloma Leuk. 2016 Nov 23. pii: S2152-2650(16)30873-4. doi: 10.1016/j.clml.2016.11.010. [Epub ahead of print].

Effects of Stress Appraisal on the Quality of Life of Adult Patients with Multiple Myeloma and Their Primary Family Caregivers in Korea.
La IS et al. Psychooncology. 2016 Dec 14. doi: 10.1002/pon.4348. [Epub ahead of print].

When to recommend a second autograft in patients with relapsed myeloma?
Ziogas DC et al. Leuk Lymphoma. 2016 Nov 28:1-7. [Epub ahead of print].

Salvage therapy in first relapse: a retrospective study in a large patient population with Multiple Myeloma.
Offidani M et al. Eur J Haematol. 2016 Nov 28. doi: 10.1111/ejh.12834. [Epub ahead of print].

Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
Salvini M et al. Expert Rev Anticancer Ther. 2017 Jan;17(1):75-87. Epub 2016 Dec 9.

Concomitant multiple myeloma, gastric adenocarcinoma and Evan’s syndrome in a patient presenting with anaemia.
Al-Ammari M et al. BMJ Case Rep. 2016 Dec 15;2016. pii: bcr2016217697. doi: 10.1136/bcr-2016-217697.

HIV Infection, Immune Suppression and Age at Diagnosis of Non-AIDS-Defining Cancers.
Shiels MS et al. Clin Infect Dis. 2016 Dec 10. pii: ciw764. [Epub ahead of print].

The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies.
Statler A et al. Leukemia. 2016 Dec 7. doi: 10.1038/leu.2016.374. [Epub ahead of print].

Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality.
Rosenblatt J et al. Blood. 2016 Dec 5. pii: blood-2016-08-731885. [Epub ahead of print].

Checkpoint inhibition in myeloma.
Benson DM Jr et al. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):528-533.

Cellular and vaccine immunotherapy for multiple myeloma.
Garfall AL et al. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):521-527.

Advances and practical use of monoclonal antibodies in multiple myeloma therapy.
Lee HC et al. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):512-520.

Role of stem cell transplant and maintenance therapy in plasma cell disorders.
McCarthy PL et al. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):504-511.

Sequencing of nontransplant treatments in multiple myeloma patients with active disease.
Yee AJ et al. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):495-503.

Myeloma: management of the newly diagnosed high-risk patient.
Dispenzieri A et al. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):485-494.

Examining temporal effects on cancer risk in the International Nuclear Workers’ Study (INWORKS).
Daniels RD et al. Int J Cancer. 2016 Dec 3. doi: 10.1002/ijc.30544. [Epub ahead of print].

Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.
Berenson A et al. Ann Hematol. 2016 Dec 2. [Epub ahead of print].

Histone deacetylases (HDAC) in physiological and pathological bone remodelling.
Cantley MD et al. Bone. 2016 Nov 30;95:162-174. doi: 10.1016/j.bone.2016.11.028. [Epub ahead of print].

Excess weight as a risk factor common to many cancer sites: words of caution when interpreting meta-analytic evidence.
Arnold M et al. Cancer Epidemiol Biomarkers Prev. 2016 Dec 1. pii: cebp.0940.2016. [Epub ahead of print].

Prevalence and Mortality-Related Factors of Multiple Myeloma in Taiwan.
Chen JH et al. PLoS One. 2016 Dec 1;11(12):e0167227. doi: 10.1371/journal.pone.0167227. eCollection 2016.

New agents in HSC mobilization.
Domingues MJ et al. Int J Hematol. 2016 Nov 30. [Epub ahead of print].

‘Trained immunity’: consequences for lymphoid malignancies.
Stevens WB et al. Haematologica. 2016 Dec;101(12):1460-1468.